“…Few studies have been performed on the anticancer activity of ruthenium (II) polypyridyl complexes [6][7][8][9][10][11][12]. Therefore, the potential use of ruthenium complexes for cancer treatment has motivated our research group to synthesize new ruthenium complexes of this class and to test them against a range of tumor cells, yielding promising results [13][14][15][16][17][18][19]. In this paper, we describe the results of biological studies of the complexes cis-[RuCl(BzCN)(bipy)(dppe)]PF 6 (1), cis-[RuCl(BzCN)(bipy)(dppb)]PF 6 (2), cis-[RuCl(BzCN)(bipy)(dppf)] PF 6 (3) and cis-[RuCl(BzCN)(phen)(dppb)]PF 6 (4) [ BzCN = benzonitrile; bipy = 2,2`-bipyridine; phen = 1,10-phenanthroline; dppe = 1,2-bis(diphenylphosphino)ethane dppb = 1,4-bis-(diphenylphosphino) butane; dppf = 1,1`-bis(diphenylphosphino)ferrocene].…”